Clinical Trials Logo
  1. Home
  2. Acute Leukemia
  3. NCT04084327
  4. Details
NCT04084327 Clinical Trial

Immunophenotyping of Acute b Cell Lymphoblstic Leukemia

Acute Leukemia Clinical Trial

Official title:
Immunophenotyping of Acute b Cell Lymphoblastic Leukemia

Clinical Trial Details — Status: Not yet recruiting

Administrative data
NCT number NCT04084327
Other study ID # acute b All
Secondary ID
Status Not yet recruiting
Phase
First received
Last updated
Start date September 1, 2019
Est. completion date December 1, 2022

Study information
Verified date October 2018
Source South Egypt Cancer Institute
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

To study the immunophenotyping pattern of acute B lymphoblastic leukemia in south Egypt Cancer Institute iand its correlation with disease outcome

Description:

study the immunophenotyping pattern of acute B lymphoblastic leukemia in south Egypt Cancer Institute from 2009 -2019 and its correlation with disease outcome

Recruitment information / eligibility
Status Not yet recruiting
Enrollment 50
Est. completion date December 1, 2022
Est. primary completion date December 1, 2020
Accepts healthy volunteers No
Gender All
Age group 12 Months to 80 Years
Eligibility Inclusion Criteria:

- New cases admitted to SECI Who didn`t receive treatment.Age above 1 years old.

Exclusion Criteria:

- Cases who received treatment Patients below 1 years old.Patients diagnosed as AML or T-ALL

Study Design

Related Conditions & MeSH terms

Intervention

Other:
• stastical analysis
1-Clinical examination data-Complete Blood Count (CBC).Bone Marrow Aspiration (BMA)-Bone Marrow Biopsy (BMB). (if available)-Immunophenotyping results (IPT).Cytogenetic results

Locations
Country Name City State
n/a

Sponsors (1)
Lead Sponsor Collaborator
South Egypt Cancer Institute

References & Publications (1)

Keegan A, Charest K, Schmidt R, Briggs D, Deangelo DJ, Li B, Morgan EA, Pozdnyakova O. Flow cytometric minimal residual disease assessment of peripheral blood in acute lymphoblastic leukaemia patients has potential for early detection of relapsed extramedullary disease. J Clin Pathol. 2018 Jul;71(7):653-658. doi: 10.1136/jclinpath-2017-204828. Epub 2018 Mar 27. — View Citation

Outcome
Type Measure Description Time frame Safety issue
Primary overall survival outcome overall survival outcome 10 years
Primary Disease-free survival outcome Disease-free survival outcome 10 years
Primary association of novel CD markers with old markers for assessment of disease outcome association of novel CD markers with old markers for assessment of disease outcome 10 years
See also
  Status Clinical Trial Phase
Recruiting NCT05088356 - Reduced Intensity Allogeneic HCT in Advanced Hematologic Malignancies w/T-Cell Depleted Graft Phase 1
Recruiting NCT04904588 - HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation With Post-Transplantation Cyclophosphamide Phase 2
Recruiting NCT04969601 - Anti-Covid-19 Vaccine in Children With Acute Leukemia and Their Siblings Phase 1/Phase 2
Recruiting NCT02356159 - Study of Palifermin (Kepivance) in Persons Undergoing Unrelated Donor Allogeneic Hematopoietic Cell Transplantation Phase 1/Phase 2
Withdrawn NCT05170828 - Cryopreserved MMUD BM With PTCy for Hematologic Malignancies Phase 1
Terminated NCT02877082 - Tacrolimus, Bortezomib, & Thymoglobulin in Preventing Low Toxicity GVHD in Donor Blood Stem Cell Transplant Patients Phase 2
Active, not recruiting NCT01956630 - Clinical Study of DC Plus CIK for Patients With Relapse Acute Leukemia After Allo-HSCT Phase 1/Phase 2
Completed NCT00988013 - Intensity Modulated Total Marrow Irradiation (IM-TMI) for Advanced Hematologic Malignancies N/A
Enrolling by invitation NCT01728402 - Pathogenesis of Hematologic Malignancies
Active, not recruiting NCT03595800 - Extension of a Study of Allogeneic Hematopoietic Stem Cell Transplantation From One Haplotype Mismatch Related Donor or From an Unrelated Donor to Younger Patients Eligible for Reduced-intensity Conditioning Regimen Phase 3
Completed NCT02440178 - Micafungin Prophylaxis During 1st Induction Chemotherapy for De Novo Acute Leukemia Phase 2
Recruiting NCT05071482 - Flumatinib Versus Imatinib Combined With Chemotherapy for de Novo Ph+ ALL Phase 4
Withdrawn NCT03138395 - iCare3: Monitoring Circulating Cancer DNA After Chemotherapy in MDS and AML N/A
Completed NCT03042676 - Electronic Database for the Follow up of the ATG_FamilyStudy
Completed NCT04597086 - Bright White Light Therapy for the Improvement of Sleep, Fatigue, Distress, Depression, and Anxiety in Hospitalized Leukemia Patients N/A
Terminated NCT03588936 - Nivolumab and Tocilizumab for Relapsed Hematological Malignancy Post-allogeneic Transplant Phase 1
Recruiting NCT05521204 - Olverembatinib for FGFR1-rearranged Neoplasms Phase 2
Terminated NCT00852709 - Phase I Dose-Escalation Trial of Clofarabine Followed by Escalating Doses of Fractionated Cyclophosphamide in Children With Relapsed or Refractory Acute Leukemias Phase 1
Not yet recruiting NCT06026839 - Longitudinal Study on the QoL of Pediatric Patients After HSCT and Its Influencing Factors
Completed NCT00520130 - Chemotherapy and Unrelated Donor Stem Cell Transplantation for Patients With Cancers of the Blood and Immune System Phase 1/Phase 2